How to Get Vyleesi (Bremelanotide) in Vermont

What Vyleesi Is and Who the FDA Approval Covers

Vyleesi is the brand name for bremelanotide, a melanocortin receptor agonist. The current FDA label limits its indication to premenopausal women with acquired, generalized HSDD: low desire that developed after a period without desire problems, occurs across situations or partners, and causes marked distress or interpersonal difficulty. The low desire must not be better explained by a medical or psychiatric condition, a relationship problem, or a medication or drug.

Vyleesi is not FDA-approved for postmenopausal women, men, children, or sexual-performance enhancement. Those boundaries matter during an access evaluation because a prescription request alone does not establish that the labeled diagnosis is present.

What the Clinical Trials Found

The two phase 3 RECONNECT trials randomized 1,247 premenopausal women with acquired, generalized HSDD. Compared with placebo, bremelanotide produced statistically significant improvements in the Female Sexual Function Index desire score and in distress related to low desire. The current label also reports that the treatment groups did not differ significantly in change in the number of satisfying sexual events, a secondary endpoint. That is a more complete account of the evidence than describing the drug as a guaranteed or dramatic response [1].

Step-by-Step: How to Get Vyleesi in Vermont

1. Find a Prescriber Authorized for a Vermont Patient

A physician, advanced practice registered nurse, physician assistant, or other clinician may prescribe only when their Vermont credentials and professional scope permit it. For telehealth, the relevant location is the patient's location during the visit. An out-of-state clinician who is not otherwise licensed in Vermont generally needs a Vermont telehealth license, telehealth registration, or another applicable authorization under 26 V.S.A. chapter 56.

Before booking, ask the practice:

• Is the clinician authorized to treat a patient who will be physically located in Vermont?
• Does the visit include a live clinical evaluation rather than only a static questionnaire?
• Will the practice submit a prior authorization or respond to an insurer's request for records if necessary?
• Where will the prescription be sent, and who handles benefit verification?

2. Complete an HSDD Evaluation

Vermont law permits prescribing after an appropriate examination performed in person, through telemedicine, or through qualifying electronic diagnostic methods. Electronic prescribing is held to the same professional standard as an in-person setting under 18 V.S.A. § 9361.

The evaluation is more than a request for a drug. A clinician will typically clarify whether low desire is acquired and generalized, whether it is distressing, and whether another factor better explains it. A medication review, sexual and relationship history, mental-health assessment, reproductive status, blood-pressure measurement, and relevant medical history can all change the diagnosis or treatment choice. The 2026 International Consultation on Sexual Medicine recommendations support a biopsychosocial evaluation rather than a medication-only approach [2].

The five-question Decreased Sexual Desire Screener is one validated tool a clinician may use, but it does not replace clinical judgment [3]. There is no FDA-required laboratory panel for Vyleesi. Tests such as thyroid or prolactin studies may be ordered when the history or examination suggests a possible contributor; they are not universal prerequisites.

3. Review Label-Specific Eligibility and Risks

The current label contraindicates Vyleesi in people with uncontrolled hypertension or known cardiovascular disease. It advises clinicians to consider cardiovascular risk, confirm that blood pressure is well controlled before treatment, and reassess it periodically. This is why a legitimate access visit should include more than a prescription transaction.

The clinician should also review pregnancy plans, contraception, kidney or liver problems, and all oral medicines. Vyleesi may slow gastric emptying and alter absorption of some oral drugs. The label specifically says to avoid it with oral naltrexone used for alcohol or opioid addiction because reduced naltrexone exposure could cause treatment failure.

4. Send the Prescription and Verify Coverage

The current Vyleesi access page directs prescribers to send prescriptions to BlinkRx. BlinkRx then contacts the patient, checks the copay and necessary approvals, applies any available savings for which the patient qualifies, and coordinates home delivery.

Patients are not required to assume that every insurer uses the same route. If a plan requires its own specialty pharmacy, the insurer or pharmacy-benefit manager may redirect fulfillment. Ask for the following before paying:

• Whether Vyleesi is covered under the pharmacy benefit
• Whether prior authorization or step therapy applies
• Which pharmacy is in network
• The estimated patient cost for the prescribed quantity
• Whether an exclusion can be appealed and what documentation the plan requires

5. Learn the Autoinjector and Arrange Follow-Up

The FDA instructions for use tell patients not to inject Vyleesi until trained by a healthcare provider. Each pen is single-use. It is injected under the skin of the abdomen or thigh at least 45 minutes before anticipated sexual activity. The duration of benefit after a dose and the optimal timing window have not been fully characterized, so the patient and prescriber may discuss timing based on response and adverse effects.

The label says to discontinue after 8 weeks if symptoms have not improved. A follow-up within that period can review benefit, nausea, blood pressure, skin changes, medication interactions, and whether continued treatment makes sense.

Telehealth Rules That Matter in Vermont

Vermont allows an appropriately authorized clinician to prescribe through telemedicine after an appropriate examination. It does not make every national telehealth prescriber automatically eligible to treat a Vermont patient. Under current law:

• A clinician already licensed for the relevant profession in Vermont may provide telemedicine within the limits of that license.
• An out-of-state clinician who is not otherwise licensed in Vermont generally must obtain Vermont telehealth authorization before treating a patient located in the state.
• The clinician must meet the same appropriate-practice standard that applies in a traditional setting.
• Vermont law requires documented informed consent for telemedicine, subject to statutory exceptions.

A page that says telehealth prescribing is simply “fully legal” misses these credentialing and standard-of-care conditions. Verify the individual clinician through the appropriate Vermont licensing authority rather than relying only on a platform's marketing page.

Insurance, Prior Authorization, and Vermont Medicaid

There is no reliable statewide promise that Vyleesi is covered. Formularies, employer exclusions, Medicaid policies, and prior-authorization criteria can change. A drug's absence from a public preferred-drug-list category also does not by itself prove either coverage or exclusion.

For Vermont Medicaid, use the current Green Mountain Care pharmacy resources or call member services with the drug name, strength, and NDC shown on the prescription. For a commercial plan, use the member portal or the number on the insurance card. Ask for a written coverage determination if the answer is unclear.

If authorization is required, the most useful record is usually the prescriber's actual clinical documentation: the diagnosis, reproductive status, why other causes do not better explain the symptoms, relevant medical history, and why the requested treatment is appropriate. Do not assume a universal DSM checklist, six-month rule, trial of flibanserin, or counseling requirement unless the patient's current plan publishes that exact criterion.

Savings and Cash-Pay Information

The current manufacturer page says eligible commercially insured patients may pay as little as $0 for a four-dose box and lists a $99 price for a four-dose prescription when insurance does not cover Vyleesi. Eligibility is evaluated individually; government-insured patients, including Medicaid beneficiaries, are excluded from the commercial savings program. The terms also say the program can change or end.

Treat those figures as current program terms, not a guaranteed price. Confirm the amount with BlinkRx at the time of the prescription. The manufacturer is now Cosette Pharmaceuticals, not Palatin Technologies.

Pharmacy, Delivery, and Storage

The FDA label says Vyleesi can be stored at or below 77°F (25°C), protected from light, and must not be frozen. It does not require routine refrigeration or a cold-chain shipment. The previous claim that low retail stocking was caused by cold-chain requirements was therefore incorrect.

The manufacturer currently describes home delivery through BlinkRx. Delivery timing depends on prescription processing, benefit review, inventory, and the patient's location; neither the FDA label nor Vermont law supports a universal 3-, 5-, 10-, or 21-day timeline.

Vyleesi is an FDA-approved commercially available product. This guide does not treat compounded bremelanotide as an interchangeable, routinely available, or automatically cheaper substitute. Compounded drugs are not FDA-approved, and federal law restricts when a pharmacy may compound a product that is essentially a copy of a commercially available drug. Any patient-specific compounding question requires an authorized prescriber and a properly licensed pharmacy; it should not be used to bypass coverage without a documented clinical basis.

Current Dosing and Safety Facts

Dose and Frequency

The FDA-labeled dose is 1.75 mg injected subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity. Do not use more than one dose in 24 hours. More than eight doses per month is not recommended because more frequent dosing increases cumulative blood-pressure exposure and the risk of focal hyperpigmentation.

Blood Pressure and Heart Rate

In clinical studies summarized in the label, maximal average increases were about 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after a dose, with a heart-rate reduction of up to 5 beats per minute. Values usually returned to baseline within 12 hours. The drug is contraindicated with uncontrolled hypertension or known cardiovascular disease.

Nausea

Nausea occurred in 40% of Vyleesi-treated participants in the phase 3 trials, required antiemetic treatment in 13%, and led 8% to stop treatment. The current label reports that nausea improved for most patients with the second dose. A phase 4 study found that taking oral ondansetron before Vyleesi did not reduce nausea, and the label says that pretreatment is not recommended. The prior page's recommendation to take ondansetron 4 mg before injection was therefore removed.

Hyperpigmentation

Focal darkening of the skin, including the face, gums, and breasts, occurred in 1% of participants using up to eight doses monthly in the phase 3 trials. It was more likely in people with darker skin and may not fully resolve after stopping. The label advises considering discontinuation if hyperpigmentation develops.

Oral-Medicine Interactions

Because Vyleesi can slow gastric emptying, it may reduce the rate or extent of absorption of oral medicines. The label advises avoiding Vyleesi when an oral drug depends on reaching a threshold concentration for effectiveness, such as an antibiotic, and considering discontinuation if a fast-acting oral medicine is delayed. Oral naltrexone used for alcohol or opioid addiction is a specific avoid combination in the label.

What to Expect From Treatment

Vyleesi is not a guaranteed response. In the phase 3 trials, desire and distress scores improved more than with placebo, but the average treatment differences were modest and there was no significant advantage for the secondary endpoint of satisfying sexual events. The most useful question at follow-up is whether the patient experiences a meaningful improvement that outweighs adverse effects and treatment burden. If there is no reported symptom improvement after eight weeks, the FDA label says to stop.